European Society for Medical Oncology

The European Society for Medical Oncology (ESMO) is a professional organisation focused on medical oncology and the wider advancement of cancer care. Founded in 1975, it serves oncology professionals in Europe and around the world, with more than 50,000 members representing the international oncology community. Its work spans scientific communication, clinical education, professional development, evidence-based treatment guidance, and the exchange of knowledge among specialists involved in cancer research and patient care. ESMO's activities are organised around several major knowledge and education platforms. Its flagship scientific journal, Annals of Oncology, was established in 1990 and publishes research and clinical material covering medical oncology, surgery, radiotherapy, paediatric oncology, basic research, and the comprehensive management of malignant disease. The journal is the official publication of ESMO and, from 2008, also became the official journal of the Japanese Society for Medical Oncology. Through the journal and associated scientific communications, ESMO provides a channel for disseminating findings across laboratory, translational, and clinical oncology. The society's ESMO Clinical Practice Guidelines are designed to translate evidence-based medicine into practical recommendations for oncology professionals. The guidelines address subjects including disease incidence, diagnostic criteria, staging, risk assessment, treatment planning, and follow-up. Their purpose is to support consistent standards of cancer care while helping clinicians interpret rapidly changing evidence and apply it in practice. ESMO also convenes scientific meetings, most prominently the annual ESMO Congress. The congress brings together approximately 30,000 participants and presents developments in basic, translational, and clinical cancer research. In addition to reporting new findings, the meeting is intended to place scientific advances in the context of everyday patient care. Other educational activities include handbooks, scientific meeting reports, medical oncology training guidelines, fellowships for research training, and an examination in medical oncology. Professional accreditation is another part of ESMO's scope. The society operates an accreditation programme for institutes providing integrated supportive and palliative care, reflecting an approach to oncology that extends beyond anticancer treatment alone. It also maintains an online professional networking platform through which members can exchange information and collaborate on research and clinical-practice issues. In 2015, ESMO introduced the Magnitude of Clinical Benefit Scale, known as ESMO-MCBS. The scale was developed to assess the clinical value of cancer therapies by considering factors such as treatment efficacy, long-term survival, and adverse effects within a single structured framework. Version 1.1 was published in 2017. The scale is intended to support interpretation of the practical value of anticancer medicines and to contribute to evidence-informed discussions about treatment choices and health-care priorities. ESMO's role is therefore broader than that of a conference organiser or publisher. It functions as a professional and scientific network linking cancer researchers, clinicians, educators, and institutions. Its principal outputs include journals, guidelines, meetings, educational programmes, examinations, fellowships, accreditation activities, and assessment tools. The available reference material does not establish a separate commercial parent, public listing, or corporate ownership structure; ESMO is described as a professional organisation rather than a conventional consumer brand.

The European Society for Medical Oncology was established in 1975 as a professional organisation dedicated to medical oncology. From its European base, the society developed an international role serving oncology professionals involved in cancer research, diagnosis, treatment, education, and patient support. The available reference material describes ESMO as having more than 50,000 members worldwide, indicating that its activities extend well beyond a narrowly regional membership. A major development in ESMO's institutional history was the creation of Annals of Oncology in 1990. The journal became the society's flagship scientific publication and provided a formal channel for publishing work across the multidisciplinary field of cancer care. Its scope includes medical oncology, surgery, radiotherapy, paediatric oncology, basic research, and the broader management of malignant diseases. In 2008, the journal also became the official journal of the Japanese Society for Medical Oncology, strengthening its connection with the international oncology community. ESMO subsequently expanded its role in clinical education and evidence implementation through the ESMO Clinical Practice Guidelines. These guidelines are structured to help oncology professionals apply evidence-based recommendations to patient care. They cover the presentation and incidence of malignancies, diagnostic standards, staging, risk assessment, treatment approaches, and follow-up. Their development reflects the society's emphasis on connecting scientific evidence with practical clinical decision-making. The annual ESMO Congress became a central forum for presenting and discussing advances in cancer research. According to the reference material, the meeting attracts approximately 30,000 participants and covers basic, translational, and clinical research. The congress also seeks to interpret new findings for implementation in routine patient care, combining the functions of a scientific meeting and a professional education platform. ESMO's educational programme broadened through handbooks, meeting reports, training guidelines, research fellowships for younger oncologists, and an examination in medical oncology. The society also established an accreditation programme for institutes offering integrated supportive and palliative care. These activities show an institutional focus on professional standards and the full continuum of cancer management, including the needs of patients whose care requires symptom control, supportive treatment, or palliation. In 2015, ESMO introduced the first version of its Magnitude of Clinical Benefit Scale. The ESMO-MCBS was designed to grade the clinical value of anticancer therapies using a structured assessment that incorporates efficacy, long-term survival, and treatment side effects. A revised version, known as version 1.1, was published in 2017. This initiative added a formal value-assessment tool to ESMO's existing work in research dissemination, guidelines, and professional education. ESMO also supports online professional networking, enabling members to exchange information and collaborate on research and clinical-practice topics. Taken together, its history reflects the development of a multidisciplinary oncology society into an international platform combining scientific publishing, congresses, clinical guidance, training, professional assessment, fellowships, institutional accreditation, and structured evaluation of treatment benefit. The supplied sources do not provide a detailed account of governance changes, individual officeholders, headquarters history, or later organisational milestones.

• 2017

  ESMO-MCBS version 1.1 published

  [1]European Society for Medical Oncologyen.wikipedia.org

  The society updated its clinical-benefit assessment framework with publication of ESMO-MCBS version 1.1.

• 2015

  ESMO-MCBS introduced

  [1]European Society for Medical Oncologyen.wikipedia.org

  ESMO published the first version of its Magnitude of Clinical Benefit Scale for structured assessment of the value of cancer therapies.

• 2008

  Journal affiliation expanded

  [1]European Society for Medical Oncologyen.wikipedia.org

  Annals of Oncology became the official journal of the Japanese Society for Medical Oncology in addition to its role as ESMO's official journal.

• 1990

  Annals of Oncology established

  [1]European Society for Medical Oncologyen.wikipedia.org

  ESMO's flagship scientific journal, Annals of Oncology, was founded to publish multidisciplinary research and clinical material relating to cancer and its management.

• 1975

  Organisation founded

  [1]European Society for Medical Oncologyen.wikipedia.org

  The European Society for Medical Oncology was founded as a professional organisation dedicated to medical oncology.

A global professional and scientific society for oncology specialists, positioned around evidence-based cancer care, clinical education, research exchange, and the translation of new scientific findings into practice.

• Scientific journal · 1990

  Annals of Oncology

  ESMO's flagship scientific journal, founded in 1990. It publishes work spanning medical oncology, surgery, radiotherapy, paediatric oncology, basic research, and the multidisciplinary management of malignant disease. The journal serves as a major publication channel for research and clinical knowledge associated with the oncology community.

• Clinical guidance

  ESMO Clinical Practice Guidelines

  Evidence-based recommendations intended to help oncology professionals deliver appropriate standards of care. Guidelines address disease incidence, diagnosis, staging, risk assessment, treatment planning, and follow-up, translating clinical evidence into practical decision-support material.

• Scientific conference

  ESMO Congress

  ESMO's annual congress presents developments in basic, translational, and clinical cancer research. The meeting attracts approximately 30,000 participants according to the reference material and places new scientific findings in the context of routine patient care.

• Treatment-value assessment tool · 2015

  ESMO Magnitude of Clinical Benefit Scale

  A structured framework for grading the magnitude of clinical benefit provided by cancer therapies. It incorporates treatment efficacy, long-term survival, and side effects into an assessment intended to support interpretation of the value of anticancer agents.

• Professional examination

  Medical oncology examination

  An ESMO professional assessment offering a formal examination component within the society's broader programme of medical oncology education and training.

• Healthcare accreditation

  Institutional accreditation programme

  An accreditation programme for institutes providing integrated supportive and palliative care to patients with cancer, extending ESMO's professional standards work beyond anticancer treatment alone.

1. 1European Society for Medical Oncologyen.wikipedia.org
2. 2European Society for Medical Oncology official websiteesmo.org